Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II regorafenib in unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab
KCT0006340Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Dec 2021; status: recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0006340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006340.